Catalyst
Slingshot members are tracking this event:
Agios Pharma (AGIO) to complete Phase 1 study of AG-519 in Patients With Pyruvate Kinase Deficiency in September 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
AGIO |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 09, 2016
Occurred Source:
http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=2176575
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pyruvate Kinase Deficiency, Pk Deficiency, Phase 1 Study, Ag-519, Double Blind